<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04673383</url>
  </required_header>
  <id_info>
    <org_study_id>CT026_001</org_study_id>
    <nct_id>NCT04673383</nct_id>
  </id_info>
  <brief_title>SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled Study of Intravenous Doses of SPL026 (DMT Fumarate), a Serotonergic Psychedelic, in Healthy Subjects (Part A) and Patients With Major Depressive Disorder (Part B)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Small Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Small Pharma Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPL026 (N,N-dimethyltryptamine [DMT] fumarate) is a psychedelic tryptamine being developed as&#xD;
      a therapy for patients with major depressive disorder (MDD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2-part study. Part A in psychedelic-naïve healthy volunteers. Part B in patients with MDD who&#xD;
      score moderate-severe on Ham-D.&#xD;
&#xD;
      Healthy volunteers will receive a single dose of SPL026 in a dose-escalation parallel group&#xD;
      study.&#xD;
&#xD;
      Patients will receive up to 2 single doses of SPL026, 2 weeks apart. Dose 1 will be&#xD;
      randomised double-blind with placebo. Dose 2 will be open label, active SPL026.&#xD;
&#xD;
      SPL026 will be administered by IV injection. Safety and tolerability, PK, PD and efficacy&#xD;
      will be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>RCT</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability in healthy volunteers</measure>
    <time_frame>Up to three months after a single dose</time_frame>
    <description>Safety and tolerability measured by lab biochemistry, adverse events and intensity rating scale to measure tolerability of the psychedelic experience</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of SPL026 in MDD patients with moderate to severe depression</measure>
    <time_frame>2 weeks after a single dose</time_frame>
    <description>Montgomery-Åsberg Depression Rating Scale (MADRS) score (where 7 - 19 is mild depression, 20 - 34 is moderate depression, and &gt;34 is severe depression) change from baseline at 2 weeks after the first dose (± 2 days)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers (active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPL026 to be administered by IV injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers (placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPL026-matched placebo to be administered by IV injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients (active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPL026 to be administered by IV injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients (placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPL026-matched placebo to be administered by IV injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPL026</intervention_name>
    <description>Intravenous solution</description>
    <arm_group_label>Healthy volunteers (active)</arm_group_label>
    <arm_group_label>Patients (active)</arm_group_label>
    <other_name>DMT</other_name>
    <other_name>dimethyltryptamine</other_name>
    <other_name>n,n-dimethytryptaimine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SPL026-matched placebo</description>
    <arm_group_label>Healthy volunteers (placebo)</arm_group_label>
    <arm_group_label>Patients (placebo)</arm_group_label>
    <other_name>Dummy</other_name>
    <other_name>SPL026-matched placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Normotensive male or female, deemed healthy on the basis of a clinical history, physical&#xD;
        examination, ECG, vital signs, laboratory tests of blood and urine, Mini-International&#xD;
        Neuropsychiatric Interview (MINI) and Beck Scale for Suicidal Ideation (BSS); willing to&#xD;
        follow the contraception requirements of the trial; willing to refrain from psychedelic&#xD;
        drug use (excluding the study drug) during the trial and ≥ 3 months afterwards; willing to&#xD;
        be contacted by email and video call, and have online access; able to give fully informed&#xD;
        written consent. Part A only: psychedelic-naïve, ie have never taken a serotonergic&#xD;
        psychedelic drug, in any form. Must be 25 years or older. Part B only: MDD diagnosis (as&#xD;
        per DSM-V); not on antidepressant medication or willing to discontinue antidepressant&#xD;
        medication (eg selective serotonin reuptake inhibitor [SSRI] treatment) for a sufficient&#xD;
        time before and during the study; no psychedelic drug use in the 6 months before dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pre-menopausal females who are pregnant or lactating, or who are sexually active and not&#xD;
        using a reliable method of contraception; clinically relevant abnormal findings at the&#xD;
        screening assessment; acute or chronic illness (other than MDD [Part B only]) or infection;&#xD;
        clinically relevant abnormal medical history or concurrent medical condition (other than&#xD;
        MDD [Part B only]); positive tests for hepatitis B &amp; C, or HIV; severe adverse reaction to&#xD;
        any drug; use of over-the-counter or prescribed medication (excluding oral contraceptives)&#xD;
        within previous 28 days (paracetamol [acetaminophen] permitted up to 7 days, and&#xD;
        antidepressant medication must have ceased for at least 14 days; 28 days for MOAIs) before&#xD;
        first dose of trial medication; drug or alcohol abuse; use of cannabis in the 24 h before&#xD;
        each study visit; heavy smokers (&gt; 10 [Part A] or &gt; 20 cigarettes [Part B] daily); supine&#xD;
        blood pressure, heart rate, or QTcF outside the acceptable ranges; participation in other&#xD;
        clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the&#xD;
        previous 3 months; phobia of needles or blood; possibility that volunteer will not&#xD;
        cooperate with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Steiner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oxford Therapeutics Consulting</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Erritzoe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malcolm Boyce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Manager</last_name>
    <phone>08007838792</phone>
    <email>recruit@hmrlondon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen James, PhD</last_name>
    <phone>07878900470</phone>
    <email>ellen.james@smallpharma.co.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Liverpool</city>
        <zip>L34 1BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Westhead, MD</last_name>
      <email>info@researchforyou.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm Boyce, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N,N-Dimethyltryptamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan for this yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

